VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers
On May24, 2017, the Board of Directors, or the Board, of
VIVUS,Inc., or the Company, appointed Thomas B. King as a
director of the Company. The Board has determined that Mr.King is
independent of the Company and its management as defined by the
Securities and Exchange Commission and the NASDAQ Listing Rules.
There were no arrangements or understandings between Mr.King and
any other persons to which he was elected as a director. There
are no family relationships between Mr.King and any director or
executive officer of the Company, and he has no direct or
indirect material interest in any transaction required to be
disclosed to Item 404(a)of Regulation S-K. Mr.Kings compensation
is expected to be consistent with that provided to all of the
Companys non-employee directors, as described in the Companys
Annual Report on Form10-K/A filed with the Securities and
Exchange Commission on April26, 2017. Mr.King has not been
appointed to any Board committee at this time.
Additional information about Mr.King is set forth below:
Mr.Kinghas served as an independent biotechnology consultant
since August2016. Previously, Mr.King served as President, Chief
Executive Officer and a member of the board of directors of
Alexza Pharmaceuticals,Inc., a publicly-traded pharmaceutical
company, from June2003 to August2016. From October2015 to
July2016, Mr.King also served as Chief Financial Officer and
Chief Accounting Officer of Alexza Pharmaceuticals,Inc. From
September2002 to April2003, Mr.King served as President, Chief
Executive Officer and a member of the board of directors of
Cognetix,Inc., a privately-held biopharmaceutical
development-stage company. From January1994 to February2001,
Mr.King held various senior executive positions at Anesta
Corporation, a publicly-traded pharmaceutical company, including
President and Chief Executive Officer from January1997 to
October2000, and was a member of the board of directors until it
was acquired by Cephalon,Inc., a publicly-traded
biopharmaceutical company. Mr.King currently serves on the board
of directors of Faraday Pharmaceuticals,Inc., a privately-held
biotechnology company. Mr.King also serves as a mentor at SPIRE
Bioventures, a multi-disciplinary consortium aiding biotechnology
entrepreneurs, and as an Advisory Board Member of the University
of Colorado BioFrontiers Institute. Mr.King received a B.A. in
chemistry from McPherson College and an M.B.A. from the
University of Kansas Graduate School of Business.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release issued by VIVUS,Inc. dated May24, 2017. |
About VIVUS, INC. (NASDAQ:VVUS)
VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity. VIVUS, INC. (NASDAQ:VVUS) Recent Trading Information
VIVUS, INC. (NASDAQ:VVUS) closed its last trading session down -0.02 at 1.10 with 1,053,329 shares trading hands.